Identify markers predicting Parkinson progression
- Trial ID
- NCT02305147
- Official Title
- Etude Des Facteurs Prédictifs De L'apparition Et De L'évolution De La Maladie De Parkinson
- Goal
- Identify markers predicting Parkinson progression
- Status
- RECRUITING
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Study Type
- OBSERVATIONAL
- Enrollment
- 360 participants
- Conditions
- Parkinson Disease
- Interventions
- Clinical, biological and imaging followup
Plain-Language Summary
The goal is to find clinical, biological, imaging and genetic markers that predict who will develop Parkinson's and how quickly the disease will progress. Participants have regular clinical exams, blood and genetic tests, MRI scans and dopamine transporter SPECT imaging, with SPECT measuring loss of dopamine nerve terminals and MRI checking brain structure so researchers can link symptoms to measurable changes over time. The trial is enrolling adults 18 and older in four groups: people with recent idiopathic Parkinson's diagnosed under 3 years ago, people with confirmed PD gene mutations, people at higher risk such as those with idiopathic REM sleep behavior disorder or relatives of genetically confirmed patients, and healthy volunteers. Key requirements include a normal basic cognitive screen, no contraindication to MRI or SPECT, and no drug-induced or atypical parkinsonism or recent neuroleptic use.
Locations
- Hôpital Pitié-Salpêtrière, Paris, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinical, biological and imaging followup. The goal is to find clinical, biological, imaging and genetic markers that predict who will develop Parkinson's and how quickly the disease will progress. Participants have regular clinical exams, blood and genetic tests, MRI scans and dopamine transporter SPECT imaging, with SPECT measuring loss of dopamine nerve terminals and MRI checking brain structure so researchers can link symptoms to measurable changes over time. The trial is enrolling adults 18 and older in four groups: people with recent idiopathic Parkinson's diagnosed under 3 years ago, people with confirmed PD gene mutations, people at higher risk such as those with idiopathic REM sleep behavior disorder or relatives of genetically confirmed patients, and healthy volunteers. Key requirements include a normal basic cognitive screen, no contraindication to MRI or SPECT, and no drug-induced or atypical parkinsonism or recent neuroleptic use.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 15 years.